Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open Label, Multicenter Study of the Safety and Efficacy of Oral Treatment With Immediate Release Seletracetam (ucb 44212) at Individualized Doses Up to a Maximum of 160mg/Day in Refractory Epileptic Patients.

Next Previous
X
Search
Trial Profile

Open Label, Multicenter Study of the Safety and Efficacy of Oral Treatment With Immediate Release Seletracetam (ucb 44212) at Individualized Doses Up to a Maximum of 160mg/Day in Refractory Epileptic Patients.

Status: Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 30 Oct 2014

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Seletracetam (Primary)
  • Indications Epilepsy
  • Focus Adverse reactions
  • Sponsors UCB Pharma Inc

    • Most Recent Events

    • 23 Nov 2006 Status change from Initiated to withdrawn prior to recruitment
    • 17 Dec 2005 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top